Yanglan Chen1, Rong Cong2, Chengjian Ji2, Wenhua Ruan1. 1. Department of Stomatology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang Province, China. 2. Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract
BACKGROUND: The prognostic role of the C-reactive protein (CRP) in head and neck squamous cell carcinoma (HNSCC) has not been well investigated. This meta-analysis aimed to evaluate the prognostic relevance of elevated CRP levels in patients with HNSCC. METHODS: A relevant literature search was performed in PubMed, Web of Science, and Embase up to September 1, 2020. The pooled odds ratio and hazard ratio (HR) with 95% confidence interval (CI) were applied to evaluate the difference in overall survival (OS), progress-free survival (PFS), and cancer-specific survival (CSS) between patients with high CRP and those without. The pooled odds ratio (OR) with 95% CI were used to assess the association between CRP and clinicopathological features. RESULTS: A total of 17 studies, including 4449 patients, were included. Pooled results showed that an elevated CRP was associated with worse OS (HR = 1.48, 95% CI: 1.24-1.77), CSS (HR = 1.85, 95% CI: 1.38-2.46), and PFS (HR = 1.73, 95% CI: 1.38-2.17). Male patients, lymph node metastases, and higher tumor stage were related to elevated CRP level (OR = 1.67, 95% CI: 1.34-2.09; OR = 2.40, 95% CI: 1.44-3.99; OR = 1.39, 95% CI: 1.12-1.74). CONCLUSION: Our meta-analysis demonstrated that an elevated pretreatment of CRP indicates poor prognosis in HNSCC. Therefore, CRP is an indicator of the prognosis of patients with HNSCC and can be recommended for assessing prognoses in clinical work.
BACKGROUND: The prognostic role of the C-reactive protein (CRP) in head and neck squamous cell carcinoma (HNSCC) has not been well investigated. This meta-analysis aimed to evaluate the prognostic relevance of elevated CRP levels in patients with HNSCC. METHODS: A relevant literature search was performed in PubMed, Web of Science, and Embase up to September 1, 2020. The pooled odds ratio and hazard ratio (HR) with 95% confidence interval (CI) were applied to evaluate the difference in overall survival (OS), progress-free survival (PFS), and cancer-specific survival (CSS) between patients with high CRP and those without. The pooled odds ratio (OR) with 95% CI were used to assess the association between CRP and clinicopathological features. RESULTS: A total of 17 studies, including 4449 patients, were included. Pooled results showed that an elevated CRP was associated with worse OS (HR = 1.48, 95% CI: 1.24-1.77), CSS (HR = 1.85, 95% CI: 1.38-2.46), and PFS (HR = 1.73, 95% CI: 1.38-2.17). Male patients, lymph node metastases, and higher tumor stage were related to elevated CRP level (OR = 1.67, 95% CI: 1.34-2.09; OR = 2.40, 95% CI: 1.44-3.99; OR = 1.39, 95% CI: 1.12-1.74). CONCLUSION: Our meta-analysis demonstrated that an elevated pretreatment of CRP indicates poor prognosis in HNSCC. Therefore, CRP is an indicator of the prognosis of patients with HNSCC and can be recommended for assessing prognoses in clinical work.
Authors: Teresa Magnes; Thomas Melchardt; Lukas Weiss; Christof Mittermair; Daniel Neureiter; Eckhard Klieser; Simon Gampenrieder; Gerhard Moser; Alexander Gaggl; Richard Greil; Alexander Egle Journal: PLoS One Date: 2017-07-07 Impact factor: 3.240